Fully Automated Lumipulse Plasma Amyloid and phosphorylated Tau assays for Progression to Alzheimer’s disease in Mild Cognitive Impairment patients

Anuschka Silva‐Spínola,Maria João Leitão,Isabel Santana,Alicia Nadal,Nathalie Le Bastard,Inês Baldeiras

DOI: https://doi.org/10.1002/alz.075285

2023-12-01

Abstract:Abstract Background Lumipulse G automated immunoassays represent the most widely used method for the quantification of Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF) 1 . Less invasive blood‐based markers confer a promising tool for AD diagnosis at prodromal stages (Mild Cognitive Impairment‐MCI) 2 . Highly sensitive assays for the quantification of amyloid‐beta (Aβ) and phosphorylated Tau‐181 (p‐Tau181) in blood are showing promising results 3 . In this study we evaluated the clinical performance of the available Lumipulse plasma markers for progression to AD. Method A group of 138 patients (22 neurological controls‐NC, 72 MCI and 44 AD) recruited at the Dementia Clinic of Centro Hospitalar Universitário de Coimbra (CHUC) was included. Data regarding baseline CSF levels of Ab42, Ab40, t‐Tau and p‐Tau181 was available, allowing for characterization into ATN categories 4 . Baseline Ab42, Ab40 and p‐Tau181 levels were determined in stored plasma samples using high‐throughput fully automated Lumipulse assays. Progression from MCI to AD dementia was assessed at follow‐up (mean 5.9±3.0 years; 36 converted ‐MCI‐AD/36 stable ‐MCI‐St). Result In the total cohort, correlations between CSF and plasma were moderate for p‐Tau 181 (r = 0.61, p<0.001), weak for Aβ42 (r = 0.28, p = 0.001) and non‐significant for Aβ40 (r = ‐0.05, p = 0.54). Plasma p‐Tau181 levels were significantly increased while Aβ42, Aβ42/Aβ40 and Aβ42/p‐Tau181 were significantly decreased (p<0.001) in patients classified as MCI‐AD and AD in relation both to NC and MCI‐St. Plasma p‐Tau181 showed a robust performance in differentiating NC+MCI‐St vs. MCI‐AD+AD (AUC = 0.89, 95%CI:0.83‐0.94), MCI‐St vs. MCI‐AD (AUC = 0.89, 95%CI:0.81‐0.96) and CSF A+ vs. A‐ (AUC = 0.84, 95%CI:0.77‐0.91). Plasma Aβ42/p‐Tau181 gave similar AUC results (AUCs = 0.88, 0.84 and 0.83) and showed no significant differences compared to p‐Tau181 alone (p = 0.34, 0.33 and 0.92). For MCI‐St vs. MCI‐AD, when maximizing for sensitivity (0.92, specificity 0.67), baseline plasma p‐Tau181 levels higher than 1.69 pg/mL predicted future AD dementia (HR = 11.5; 95%CI = 10.9‐12.1). Conclusion Our results show that the measurement of p‐Tau181 in peripheral blood has great potential as a non‐invasive prognostic screening tool for AD dementia in MCI patients. 1. Delaby C, et al. Alzheimer’s Dement . 2021; 2.Teunissen CE, et al. Lancet Neurol . 2022; 3.Palmqvist S, et al. Nat Med . 2021; 4.Jack CR, et al. Alzheimer’s Dement . 2018

clinical neurology